LIFE SCIENCE

We invest in early-stage companies, founded on innovative research-based technologies within pharma and medtech, with compelling value propositions serving unmet medical needs. We look for well-defined development plans with clear value inflection points, enabling robust returns on investment. 

CLEAN TECH ENERGY AND TECHNOLOGY

We invest in leading early stage science and technology based companies with technologies that can make the world a better place and accelerate the transition to a 100% renewable energy system. We look for exceptional entrepreneurs and breakthrough innovations that may have an disruptive impact on industries and markets and create value for individuals, society, industry and investors. 

Sarsia is a Norwegian early stage Venture Capital fund manager investing in technology companies within the energy / technology and biotechnology / life science sectors.

Vaccibody AS Lists on Oslo Stock Exchange

Sarsia Seed portfolio company Vaccibody AS - was today listed on Oslo Stock Exchange´s Merkur Markets list.                                                                                                                                                                 ...

Vaccibody enters into worldwide license and collaboration agreement with Genentech

It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition.             ...

Vaccibody and Nektar Therapeutics Announce First Patient Dosed in collaborative Phase 1/2a Study

Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR)  announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's...

Vaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer

Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...

Rallybio raises USD 145 mill to develop asset acquired from Prophylix Pharma

US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company's portfolio of product candidates targeting devastating rare diseases. Rallybio's lead candidate is RLYB211 that the company acquired...

BerGenBio raises Euro 45 million in over subscribed private placement

BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020.  Read more

BerGenBio’s Bemcentinib selected to be fasttracked as potential treatment for COVID-19

BerGenBio announces that bemcentinib has been selected to be fast-tracked in a new UK national multi-centre randomised Phase 2 clinicial trial initiative that aims to get an early indication of whether bemcentinib could save lives and improve outcomes in the most...

Vaccibody listed on NOTC

Vaccibody AS announces that it will register on the Norwegian OTC-list (“NOTC”), owned and operated by Oslo Børs, from  January 27. Vaccibody will trade under the ticker “VACC”. Read more

Vaccibody announces positive clinical trial results

Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine. The data is from the first 16 patients assessed for safety after treatment with a VB10.NEO, and the first 14 patients...

Bergenbio’s Bemcentinib meets primary endpoint in first cohort of Phase II NSCLC study in combination with Keytruda®

In a communication during the Annual Meeting of the Society for Immunotherapy BerGen Bio announces that the company’s drug candidate Bemcentinib meets the primary endpoint in first cohort of Phase II NSCLC study in combination with Keytruda®. The primary efficacy...